Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 9/20 | 0.37 |
| ▸ | ELANE | P08246 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1848867 | 0.82 | PPARG (0.54) | PPARGFFAR1 | |
| SCHEMBL1850303 | 0.80 | PPARG (0.58) | PPARG | |
| SCHEMBL1848404 | 0.80 | PPARG (0.52) | PPARG | |
| Water SCHEMBL6806396 | 0.80 | PPARG (0.57) | PPARG | |
| SCHEMBL1847323 | 0.79 | PPARG (0.51) | PPARG | |
| SCHEMBL1848815 | 0.79 | PPARG (0.37) | PPARGFFAR1HRH3 | |
| SCHEMBL2177889 | 0.78 | PPARG (0.51) | PPARG | |
| SCHEMBL3117526 | 0.78 | ITGB3 (0.45) | PPARGHRH3 | |
| SCHEMBL9326656 | 0.76 | HRH3 (0.48) | PPARGFFAR1HRH3 | |
| SCHEMBL1849761 | 0.75 | PPARG (0.66) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030149054-A1 | Administering thiazolidinedione derivatives for therapy and prophylaxis of cardiovascular diseases or eating disorders in a human or non- human mammal | BEECHAM GROUP P.L.C. | 2003-08-07 | — | — | US | claimed |
| US-20020049240-A1 | NOVEL COMPOUNDS | BEECHAM GROUP P.1.C. | 2002-04-25 | — | — | US | claimed |
| US-5232925-A | Treating hypertension | BEECHAM GROUP P.L.C. (GB) | 1993-08-03 | — | — | US | claimed |
| US-5002953-A | Substituted Thiazolidinedione Derivatives | BEECHAM GROUP P.L.C. (GB) | 1991-03-26 | — | — | US | claimed |
| US-11021751-B2 | Disease risk factors and methods of use | ZINFANDEL PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210095345-A1 | METHOD OF IDENTIFYING DISEASE RISK FACTORS | ZINFANDEL PHARMACEUTICALS INC (US) | 2021-04-01 | — | — | US | disclosed |
| US-10865449-B2 | Method of identifying disease risk factors | ZINFANDEL PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| EP-2789695-B1 | Anti-Alzheimer's disease treatment of subjects identified by detecting the presence of a genetic variant in the TOMM40 gene at rs 10524523 | ZINFANDEL PHARMACEUTICALS INC (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190032137-A1 | DISEASE RISK FACTORS AND METHODS OF USE | ZINFANDEL PHARMACEUTICALS, INC. (US) | 2019-01-31 | — | — | US | disclosed |
| US-20180363060-A1 | METHOD OF IDENTIFYING DISEASE RISK FACTORS | ZINFANDEL PHARMACEUTICALS, INC. (US) | 2018-12-20 | — | — | US | disclosed |
| US-20150073022-A1 | DISEASE RISK FACTORS AND METHODS OF USE | ZINFANDEL PHARMACEUTICALS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-20150073025-A1 | METHOD FOR IDENTIFYING DISEASE RISK FACTORS | ZINFANDEL PHARMACEUTICALS INC (US) | 2015-03-12 | — | — | US | disclosed |
| US-6686475-B2 | THIAZOLIDINEDIONE DERIVATIVES HAVING HYPOGLYCAEMIC AND HYPOLIPIDAEMIC ACTIVITIES | BEECHAM GROUP P.L.C. (GB) | 2004-02-03 | — | — | US | disclosed |
| US-20030149054-A1 | Administering thiazolidinedione derivatives for therapy and prophylaxis of cardiovascular diseases or eating disorders in a human or non- human mammal | BEECHAM GROUP P.L.C. | 2003-08-07 | — | — | US | disclosed |
| US-20020049240-A1 | NOVEL COMPOUNDS | BEECHAM GROUP P.1.C. | 2002-04-25 | — | — | US | disclosed |
| US-6288095-B1 | ADMINISTERING 5-(4-(2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY) BENZYL)-2,4-THIAZOLIDINEDIONE TO MAMMALS AS AN ANTIDIABETIC | BEECHAM GROUP P.L.C. (GB) | 2001-09-11 | — | — | US | disclosed |
| US-5260445-A | Hypoglycemic | BEECHAM GROUP P.L.C. (GB) | 1993-11-09 | — | — | US | disclosed |
| US-5232925-A | Treating hypertension | BEECHAM GROUP P.L.C. (GB) | 1993-08-03 | — | — | US | disclosed |
| US-5194443-A | Thiazolinediones, Hypoglycemic Agents, Antilipemic Agents | BEECHAM GROUP P.L.C. (GB) | 1993-03-16 | — | — | US | disclosed |
| US-5002953-A | Substituted Thiazolidinedione Derivatives | BEECHAM GROUP P.L.C. (GB) | 1991-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149054-A1 | Administering thiazolidinedione derivatives for therapy and prophylaxis of cardiovascular diseases or eating disorders in a human or non- human mammal | TYK2, FABP3, FABP4 | CETP 298/4885PPARG 16/4885ELANE 3556/4885 |
| US-20020049240-A1 | NOVEL COMPOUNDS | GRK1, GRK3, GRK7 | CETP 347/4885PPARG 715/4885ELANE 2110/4885 |
| US-20150073022-A1 | DISEASE RISK FACTORS AND METHODS OF USE | TSG101, TOMM40, TOMM70 | CETP 527/4885PPARG 1229/4885ELANE 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.